Akoya Biosciences amends bylaws to adopt Universal Proxy Rules and DGCL updates

Akoya Biosciences, Inc.

Enhanced disclosure requirements for stockholder director nominations and other proposals.
Requires stockholders to represent intent to solicit proxies under Rule 14a-19 for non-company nominees.
Company will disregard nominations if stockholder fails to comply with Rule 14a-19 requirements.
Prohibits placeholder nominees; white proxy card reserved exclusively for the Board.
Updates stockholder list provisions to reflect recent Delaware General Corporation Law amendments.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Akoya Biosciences, Inc.: Amended and restated bylaws to adopt Rule 14a-19 (Universal Proxy Rules), reflect recent changes to Delaware General Corporation Law, and make other updates (effective 2023-08-31).

Change: bylaw amendment
Effective: 2023-08-31

Exact text from the filing

On August 31, 2023, in connection with the adoption of Rule 14a-19 (the “Universal Proxy Rules”) under the Securities Exchange Act of 1934, as amended, certain recent changes to the Delaware General Corporation Law (the “DGCL”), and a periodic review of the bylaws of Akoya Biosciences, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) adopted amended and restated bylaws (the “Amended and Restated Bylaws”), effective immediately.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001104659-23-098637

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.